ATACAND HCT is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Astrazeneca Pharmaceuticals Lp. The primary component is Candesartan Cilexetil; Hydrochlorothiazide.
| Product ID | 0186-0322_9e314974-b835-461b-b4f4-9f3660ea83ae |
| NDC | 0186-0322 |
| Product Type | Human Prescription Drug |
| Proprietary Name | ATACAND HCT |
| Generic Name | Candesartan Cilexetil And Hydrochlorothiazide |
| Dosage Form | Tablet |
| Route of Administration | ORAL |
| Marketing Start Date | 2000-09-28 |
| Marketing End Date | 2020-12-31 |
| Marketing Category | NDA / NDA |
| Application Number | NDA021093 |
| Labeler Name | AstraZeneca Pharmaceuticals LP |
| Substance Name | CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE |
| Active Ingredient Strength | 32 mg/1; mg/1 |
| Pharm Classes | Angiotensin 2 Receptor Antagonists [MoA],Angiotensin 2 Receptor Blocker [EPC],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [CS] |
| NDC Exclude Flag | N |
| Marketing Start Date | 2000-09-28 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA021093 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2000-09-28 |
| Marketing End Date | 2020-12-31 |
| Marketing Category | NDA |
| Application Number | NDA021093 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2000-09-28 |
| Marketing End Date | 2014-10-31 |
| Ingredient | Strength |
|---|---|
| CANDESARTAN CILEXETIL | 32 mg/1 |
| SPL SET ID: | 48b021e4-5897-42fd-12be-3190a9b087e8 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0186-0162 | ATACAND HCT | Candesartan cilexetil and Hydrochlorothiazide |
| 0186-0322 | ATACAND HCT | Candesartan cilexetil and Hydrochlorothiazide |
| 0186-0324 | ATACAND HCT | Candesartan cilexetil Hydrochlorothiazide |
| 62559-650 | ATACAND HCT | Candesartan Cilexetil and Hydrochlorothiazide |
| 62559-651 | ATACAND HCT | Candesartan Cilexetil and Hydrochlorothiazide |
| 62559-652 | ATACAND HCT | Candesartan Cilexetil and Hydrochlorothiazide |
| 63629-3377 | ATACAND HCT | ATACAND HCT |
| 0378-3001 | Candesartan Cilexetil and Hydrochlorothiazide | candesartan cilexetil and hydrochlorothiazide |
| 0378-3002 | Candesartan Cilexetil and Hydrochlorothiazide | candesartan cilexetil and hydrochlorothiazide |
| 0378-3003 | Candesartan Cilexetil and Hydrochlorothiazide | candesartan cilexetil and hydrochlorothiazide |
| 33342-131 | Candesartan Cilexetil and Hydrochlorothiazide | Candesartan Cilexetil and Hydrochlorothiazide |
| 33342-132 | Candesartan Cilexetil and Hydrochlorothiazide | Candesartan Cilexetil and Hydrochlorothiazide |
| 33342-133 | Candesartan Cilexetil and Hydrochlorothiazide | Candesartan Cilexetil and Hydrochlorothiazide |
| 43547-459 | candesartan cilexetil and hydrochlorothiazide | candesartan cilexetil and hydrochlorothiazide |
| 43547-460 | candesartan cilexetil and hydrochlorothiazide | candesartan cilexetil and hydrochlorothiazide |
| 43547-461 | candesartan cilexetil and hydrochlorothiazide | candesartan cilexetil and hydrochlorothiazide |
| 62559-660 | Candesartan Cilexetil and Hydrochlorothiazide | Candesartan Cilexetil and Hydrochlorothiazide |
| 62559-661 | Candesartan Cilexetil and Hydrochlorothiazide | Candesartan Cilexetil and Hydrochlorothiazide |
| 62559-662 | Candesartan Cilexetil and Hydrochlorothiazide | Candesartan Cilexetil and Hydrochlorothiazide |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() ATACAND HCT 75250934 2485478 Live/Registered |
ASTRAZENECA AB 1997-03-03 |